The Filings Report

Eli Lilly

LLYNYSECIK 59478Healthcare / Drug Manufacturersfiscal year ends December74 quarters since 2008

Revenue, Q3 FY2026
$24.4B
+38.6% on Q3 FY2025
Net income
$6.5B
+15.5% on Q3 FY2025
Free cash flow
—
no year-earlier figure
Diluted EPS
$7.22
+16.3% on Q3 FY2025
Revenue, TTM
$86.5B
trailing four quarters
Net margin, TTM
31.9%
net income $27.6B
Free cash flow, TTM
—
Cash and equivalents
$4.9B
long-term debt $47.0B, Sep 30, 2026
Shares, 12-month change
−0.5%
941M shares, Sep 30, 2026
Buybacks, TTM
$5.8B
0.4% of market value
Dividends, TTM
$6.0B
0.5% of market value
Market value
$1.33T
at the close, buybacks

Latest quarter Q3 FY2026, filed October 29, 2026. Trailing figures sum the latest four quarters. Market values at the latest close, from a market data vendor.

In Q3 FY2026, the quarter ended September 30, 2026, Eli Lilly reported revenue of $24.4B, +38.6% on Q3 FY2025, and net income of $6.5B (+15.5%). Diluted earnings per share were $7.22.

The last 16 quarters

Q4 FY2022 to Q3 FY2026, through the filing of October 29, 2026.

Revenue and net incomeRevenueNet income
−$10B$0$10B$20B$30BQ4'22, Revenue: $7.3BQ4'22, Net income: $1.9BQ4'22Q1'23, Revenue: $7.0BQ1'23, Net income: $1.3BQ1'23Q2'23, Revenue: $8.3BQ2'23, Net income: $1.8BQ2'23Q3'23, Revenue: $9.5BQ3'23, Net income: −$57MQ3'23Q4'23, Revenue: $9.4BQ4'23, Net income: $2.2BQ4'23Q1'24, Revenue: $8.8BQ1'24, Net income: $2.2BQ1'24Q2'24, Revenue: $11.3BQ2'24, Net income: $3.0BQ2'24Q3'24, Revenue: $11.4BQ3'24, Net income: $970MQ3'24Q4'24, Revenue: $13.5BQ4'24, Net income: $4.4BQ4'24Q1'25, Revenue: $12.7BQ1'25, Net income: $2.8BQ1'25Q2'25, Revenue: $15.6BQ2'25, Net income: $5.7BQ2'25Q3'25, Revenue: $17.6BQ3'25, Net income: $5.6BQ3'25Q4'25, Revenue: $19.3BQ4'25, Net income: $6.6BQ4'25Q1'26, Revenue: $19.8BQ1'26, Net income: $7.4BQ1'26Q2'26, Revenue: $23.0BQ2'26, Net income: $7.1BQ2'26Q3'26, Revenue: $24.4BQ3'26, Net income: $6.5BQ3'26−$10B$0$10B$20B$30BQ4'22, Revenue: $7.3BQ4'22, Net income: $1.9BQ1'23, Revenue: $7.0BQ1'23, Net income: $1.3BQ1'23Q2'23, Revenue: $8.3BQ2'23, Net income: $1.8BQ3'23, Revenue: $9.5BQ3'23, Net income: −$57MQ3'23Q4'23, Revenue: $9.4BQ4'23, Net income: $2.2BQ1'24, Revenue: $8.8BQ1'24, Net income: $2.2BQ1'24Q2'24, Revenue: $11.3BQ2'24, Net income: $3.0BQ3'24, Revenue: $11.4BQ3'24, Net income: $970MQ3'24Q4'24, Revenue: $13.5BQ4'24, Net income: $4.4BQ1'25, Revenue: $12.7BQ1'25, Net income: $2.8BQ1'25Q2'25, Revenue: $15.6BQ2'25, Net income: $5.7BQ3'25, Revenue: $17.6BQ3'25, Net income: $5.6BQ3'25Q4'25, Revenue: $19.3BQ4'25, Net income: $6.6BQ1'26, Revenue: $19.8BQ1'26, Net income: $7.4BQ1'26Q2'26, Revenue: $23.0BQ2'26, Net income: $7.1BQ3'26, Revenue: $24.4BQ3'26, Net income: $6.5BQ3'26

Net income losses drawn in red.

Cash and equivalents against long-term debtCash and equivalentsLong-term debt
$0$20B$40B$60BQ4'22, Cash and equivalents: $2.1BQ4'22, Long-term debt: $14.7BQ4'22Q1'23, Cash and equivalents: $3.5BQ1'23, Long-term debt: $18.9BQ1'23Q2'23, Cash and equivalents: $2.7BQ2'23, Long-term debt: $18.2BQ2'23Q3'23, Cash and equivalents: $2.4BQ3'23, Long-term debt: $17.9BQ3'23Q4'23, Cash and equivalents: $2.8BQ4'23, Long-term debt: $18.3BQ4'23Q1'24, Cash and equivalents: $2.5BQ1'24, Long-term debt: $24.6BQ1'24Q2'24, Cash and equivalents: $3.2BQ2'24, Long-term debt: $23.7BQ2'24Q3'24, Cash and equivalents: $3.4BQ3'24, Long-term debt: $29.0BQ3'24Q4'24, Cash and equivalents: $3.3BQ4'24, Long-term debt: $28.5BQ4'24Q1'25, Cash and equivalents: $3.1BQ1'25, Long-term debt: $34.5BQ1'25Q2'25, Cash and equivalents: $3.4BQ2'25, Long-term debt: $34.2BQ2'25Q3'25, Cash and equivalents: $9.8BQ3'25, Long-term debt: $40.9BQ3'25Q4'25, Cash and equivalents: $7.3BQ4'25, Long-term debt: $40.9BQ4'25Q1'26, Cash and equivalents: $5.3BQ1'26, Long-term debt: $39.4BQ1'26Q2'26, Cash and equivalents: $8.9BQ2'26, Long-term debt: $47.9BQ2'26Q3'26, Cash and equivalents: $4.9BQ3'26, Long-term debt: $47.0BQ3'26$0$20B$40B$60BQ4'22, Cash and equivalents: $2.1BQ4'22, Long-term debt: $14.7BQ1'23, Cash and equivalents: $3.5BQ1'23, Long-term debt: $18.9BQ1'23Q2'23, Cash and equivalents: $2.7BQ2'23, Long-term debt: $18.2BQ3'23, Cash and equivalents: $2.4BQ3'23, Long-term debt: $17.9BQ3'23Q4'23, Cash and equivalents: $2.8BQ4'23, Long-term debt: $18.3BQ1'24, Cash and equivalents: $2.5BQ1'24, Long-term debt: $24.6BQ1'24Q2'24, Cash and equivalents: $3.2BQ2'24, Long-term debt: $23.7BQ3'24, Cash and equivalents: $3.4BQ3'24, Long-term debt: $29.0BQ3'24Q4'24, Cash and equivalents: $3.3BQ4'24, Long-term debt: $28.5BQ1'25, Cash and equivalents: $3.1BQ1'25, Long-term debt: $34.5BQ1'25Q2'25, Cash and equivalents: $3.4BQ2'25, Long-term debt: $34.2BQ3'25, Cash and equivalents: $9.8BQ3'25, Long-term debt: $40.9BQ3'25Q4'25, Cash and equivalents: $7.3BQ4'25, Long-term debt: $40.9BQ1'26, Cash and equivalents: $5.3BQ1'26, Long-term debt: $39.4BQ1'26Q2'26, Cash and equivalents: $8.9BQ2'26, Long-term debt: $47.9BQ3'26, Cash and equivalents: $4.9BQ3'26, Long-term debt: $47.0BQ3'26

Positions at each quarter end, as filed; short-term investments are not included.

Income statement

Last eight quarters, newest first, through Q3 FY2026 filed October 29, 2026.

Eli Lilly income statement, quarterly
Millions of dollarsQ3 FY2026ended Sep 30, 2026filed Oct 29, 2026Q2 FY2026ended Jun 30, 2026filed Aug 5, 2026Q1 FY2026ended Mar 31, 2026filed Apr 30, 2026Q4 FY2025ended Dec 31, 2025filed Feb 12, 2026Q3 FY2025ended Sep 30, 2025filed Oct 30, 2025Q2 FY2025ended Jun 30, 2025filed Aug 7, 2025Q1 FY2025ended Mar 31, 2025filed May 1, 2025Q4 FY2024ended Dec 31, 2024filed Feb 19, 2025YoYQ3 FY2026vs Q3 FY2025
Revenue24,39722,97419,79919,29217,60115,55812,72913,533+38.6%
Cost of revenue3,9333,2683,5773,3723,0082,4482,2252,404+30.8%
Gross profit—————————
Research and development—————————
Selling, general and administrative3,1253,4302,9343,1312,7412,7532,4682,425+14.0%
Operating income—————————
Other income (expense)(202)269(65)(109)(132)(90)(239)(110)−53.0%
Pretax income8,4069,2478,8508,2667,2336,7773,4565,038+16.2%
Income tax1,9552,1521,4541,6281,6501,116697629+18.5%
Net income6,4517,0957,3966,6385,5835,6612,7594,410+15.5%
Diluted EPS ($)7.227.948.26—6.216.293.06—+16.3%
Diluted shares (millions)893894896—899900901——

Fourth quarters are the fiscal year less the first nine months when the filer reports no discrete fourth quarter, and are marked. Diluted EPS is never derived, so a derived quarter shows none. Italic figures are derived.

Balance sheet

Last eight quarters, newest first, through Q3 FY2026 filed October 29, 2026.

Eli Lilly balance sheet, quarterly
Millions of dollarsQ3 FY2026ended Sep 30, 2026filed Oct 29, 2026Q2 FY2026ended Jun 30, 2026filed Aug 5, 2026Q1 FY2026ended Mar 31, 2026filed Apr 30, 2026Q4 FY2025ended Dec 31, 2025filed Feb 12, 2026Q3 FY2025ended Sep 30, 2025filed Oct 30, 2025Q2 FY2025ended Jun 30, 2025filed Aug 7, 2025Q1 FY2025ended Mar 31, 2025filed May 1, 2025Q4 FY2024ended Dec 31, 2024filed Feb 19, 2025YoYQ3 FY2026vs Q3 FY2025
Cash and equivalents4,8858,9505,2827,2689,7923,3763,0933,268−50.1%
Short-term investments————122170127155—
Total current assets65,26364,67254,83555,62962,07149,85441,26132,740+5.1%
Total assets148,072142,283116,576112,476114,935100,92389,38978,715+28.8%
Total current liabilities46,99647,74136,63435,22840,14139,02030,06828,376+17.1%
Long-term debt46,98647,85839,37040,86840,87434,18034,50028,527+15.0%
Total liabilities—————————
Stockholders’ equity40,27133,87931,19826,53523,79318,27315,76514,272+69.3%
Shares outstanding (millions)941941942943945946948948—

Positions at each period end. Nothing on this statement is derived. Long-term debt is the filed noncurrent line only; no total-debt composite is constructed across filers. Italic figures are derived.

Cash flow statement

Last eight quarters, newest first, through Q3 FY2026 filed October 29, 2026.

Eli Lilly cash flow statement, quarterly
Millions of dollarsQ3 FY2026ended Sep 30, 2026filed Oct 29, 2026Q2 FY2026ended Jun 30, 2026filed Aug 5, 2026Q1 FY2026ended Mar 31, 2026filed Apr 30, 2026Q4 FY2025ended Dec 31, 2025filed Feb 12, 2026Q3 FY2025ended Sep 30, 2025filed Oct 30, 2025Q2 FY2025ended Jun 30, 2025filed Aug 7, 2025Q1 FY2025ended Mar 31, 2025filed May 1, 2025Q4 FY2024ended Dec 31, 2024filed Feb 19, 2025YoYQ3 FY2026vs Q3 FY2025
Operating cash flow11,39710,6905,3333,2258,8353,0871,6662,474+29.0%
Capital expenditures—————————
Free cash flow (CFO − capex)—————————
Depreciation and amortization545534509586470478463485+16.0%
Share repurchases3771,6012,3561,5087086921,2002,054−46.8%
Dividends paid1,5411,5461,5481,3451,3461,3471,3461,168+14.5%

10-Qs file cash flows as year-to-date totals, so quarterly figures are differenced from consecutive filings and marked. Free cash flow is operating cash flow less capital expenditures, computed from the two filed lines. Italic figures are derived.

Annual statements

Every fiscal year filed, newest first, through FY2025 filed February 12, 2026.

Income statement

Eli Lilly income statement, annual
Millions of dollarsFY2025ended Dec 31, 2025filed Feb 12, 2026FY2024ended Dec 31, 2024filed Feb 19, 2025FY2023ended Dec 31, 2023filed Feb 21, 2024FY2022ended Dec 31, 2022filed Feb 22, 2023FY2021ended Dec 31, 2021filed Feb 23, 2022FY2020ended Dec 31, 2020filed Feb 17, 2021FY2019ended Dec 31, 2019filed Feb 19, 2020FY2018ended Dec 31, 2018filed Feb 19, 2019FY2017ended Dec 31, 2017filed Feb 20, 2018FY2016ended Dec 31, 2016filed Feb 21, 2017FY2015ended Dec 31, 2015filed Feb 19, 2016FY2014ended Dec 31, 2014filed Feb 19, 2015FY2013ended Dec 31, 2013filed Feb 19, 2014FY2012ended Dec 31, 2012filed Feb 21, 2013FY2011ended Dec 31, 2011filed Feb 24, 2012FY2010ended Dec 31, 2010filed Feb 22, 2011FY2009ended Dec 31, 2009filed Feb 22, 2010FY2008ended Dec 31, 2008filed Jul 31, 2009FY2007ended Dec 31, 2007filed Jul 31, 2009
Revenue65,17945,04334,12428,54128,31824,54022,32021,49319,97421,22219,95919,61623,11322,60324,28723,07621,83620,37218,634
Cost of revenue11,0528,4187,0826,6307,3135,4834,7214,6824,4485,710—————————
Gross profit———————————————————
Research and development———7,1916,9315,9765,5955,0515,0965,3104,7964,7345,5315,2785,0214,8844,3273,8413,487
Selling, general and administrative11,0948,5947,4046,4406,4326,1216,2145,9755,9826,5286,5336,6217,1267,5147,8807,0536,8936,6266,095
Operating income———————————————————
Other income (expense)(571)(219)97(321)(202)1,172292146302113101341519674(179)(5)(229)26122
Pretax income25,73112,6806,5546,8066,1567,2305,2663,6802,3053,3742,7903,0005,8895,4085,3506,7675,358(1,308)3,877
Income tax5,0912,0901,3145625741,0366285302,3916363826101,2051,3201,0021,4561,029764924
Net income20,64010,5905,2406,2455,5826,1948,3183,232(204)2,7382,4082,3914,6854,0894,3485,0704,329(2,072)2,953
Diluted EPS ($)22.9511.715.806.906.126.798.893.13(0.19)2.582.262.234.323.663.904.583.94(1.89)—
Diluted shares (millions)8999049039059129139361,0341,0521,0621,0661,0741,0851,1171,1141,1061,0981,094—

Balance sheet

Eli Lilly balance sheet, annual
Millions of dollarsFY2025ended Dec 31, 2025filed Feb 12, 2026FY2024ended Dec 31, 2024filed Feb 19, 2025FY2023ended Dec 31, 2023filed Feb 21, 2024FY2022ended Dec 31, 2022filed Feb 22, 2023FY2021ended Dec 31, 2021filed Feb 23, 2022FY2020ended Dec 31, 2020filed Feb 17, 2021FY2019ended Dec 31, 2019filed Feb 19, 2020FY2018ended Dec 31, 2018filed Feb 19, 2019FY2017ended Dec 31, 2017filed Feb 20, 2018FY2016ended Dec 31, 2016filed Feb 21, 2017FY2015ended Dec 31, 2015filed Feb 19, 2016FY2014ended Dec 31, 2014filed Feb 19, 2015FY2013ended Dec 31, 2013filed Feb 19, 2014FY2012ended Dec 31, 2012filed Feb 21, 2013FY2011ended Dec 31, 2011filed Feb 24, 2012FY2010ended Dec 31, 2010filed Feb 22, 2011FY2009ended Dec 31, 2009filed Feb 22, 2010FY2008ended Dec 31, 2008filed Jul 31, 2009FY2007ended Dec 31, 2007filed Jul 31, 2009
Cash and equivalents7,2683,2682,8192,0673,8193,6572,3387,3216,5364,5823,6663,8723,8304,0195,9235,9934,4635,4973,221
Short-term investments—1551091459024101881,4981,4577859551,5671,66697573435429—
Total current assets55,62932,74025,72718,03518,45217,46213,71020,55019,20215,10112,57411,92813,10513,03914,24814,84012,48712,453—
Total assets112,47678,71564,00649,49048,80646,63339,28643,90844,98138,80635,56936,30835,24934,39933,66031,00127,46129,213—
Total current liabilities35,22828,37627,29317,13815,05312,48211,77511,88814,53610,9878,2309,7418,9178,3908,9316,9276,56813,110—
Long-term debt40,86828,52718,32114,73815,34616,58713,8189,1969,9418,3687,9725,3334,2005,5195,4656,7716,6354,616—
Total liabilities———————————————————
Stockholders’ equity26,53514,27210,77210,6508,9795,6422,6079,82911,59214,00814,57115,37317,63114,76513,54212,420———
Shares outstanding (millions)9439489509509529589561,0351,0961,1031,1061,1111,1201,1341,1601,1581,153——

Cash flow statement

Eli Lilly cash flow statement, annual
Millions of dollarsFY2025ended Dec 31, 2025filed Feb 12, 2026FY2024ended Dec 31, 2024filed Feb 19, 2025FY2023ended Dec 31, 2023filed Feb 21, 2024FY2022ended Dec 31, 2022filed Feb 22, 2023FY2021ended Dec 31, 2021filed Feb 23, 2022FY2020ended Dec 31, 2020filed Feb 17, 2021FY2019ended Dec 31, 2019filed Feb 19, 2020FY2018ended Dec 31, 2018filed Feb 19, 2019FY2017ended Dec 31, 2017filed Feb 20, 2018FY2016ended Dec 31, 2016filed Feb 21, 2017FY2015ended Dec 31, 2015filed Feb 19, 2016FY2014ended Dec 31, 2014filed Feb 19, 2015FY2013ended Dec 31, 2013filed Feb 19, 2014FY2012ended Dec 31, 2012filed Feb 21, 2013FY2011ended Dec 31, 2011filed Feb 24, 2012FY2010ended Dec 31, 2010filed Feb 22, 2011FY2009ended Dec 31, 2009filed Feb 22, 2010FY2008ended Dec 31, 2008filed Jul 31, 2009FY2007ended Dec 31, 2007filed Jul 31, 2009
Operating cash flow16,8138,8184,2407,5867,3666,5004,8375,5255,6164,8512,9654,4585,7355,3057,2356,8574,3367,2965,155
Capital expenditures———————————————————
Free cash flow (CFO − capex)———————————————————
Depreciation and amortization1,9971,7671,5271,5231,5481,3241,2331,6091,5671,4971,4281,3791,4461,4621,3741,3281,2981,123(1,048)
Share repurchases4,1082,5007501,5001,2505004,4004,1513006007508001,69872100———
Dividends paid5,3844,6804,0693,5363,0872,6872,4102,3122,1922,1592,1272,1012,1212,1872,1802,1652,1522,0571,854

Insider activity

Form 4 filings by officers, directors and 10% owners, November 1, 2024 to November 1, 2026. Only open-market purchases and sales count as buys and sells; awards, exercises, tax withholding and gifts are listed in grey and never counted.

Bought, three months
$0
0 purchases by 0 insiders; officers and directors $0
Sold, three months
$16M
3 sales by 3 insiders; officers and directors $16M
Bought, twelve months
$0
0 purchases by 0 insiders; officers and directors $0
Sold, twelve months
$78.1B
240 sales by 5 insiders; officers and directors $20M

The last 25 transactions

TradedInsiderRoleTransactionSharesPriceValueHeld afterFiled
Oct 19, 2026Sulzberger GabrielleDirectoraward4$1240.34$5K3,016Oct 20, 2026
Oct 19, 2026Luciano Juan RDirectoraward13$1240.34$16K16,970Oct 20, 2026
Oct 19, 2026Fyrwald J ErikDirectoraward8$1240.34$10K75,544Oct 20, 2026
Oct 19, 2026Alvarez RalphDirectoraward10$1240.34$12K55,848Oct 20, 2026
Sep 21, 2026Sulzberger GabrielleDirectoraward4$1164.89$5K3,012Sep 22, 2026
Sep 21, 2026Luciano Juan RDirectoraward14$1164.89$16K16,957Sep 22, 2026
Sep 21, 2026Fyrwald J ErikDirectoraward9$1164.89$10K75,536Sep 22, 2026
Sep 21, 2026Alvarez RalphDirectoraward11$1164.89$12K55,838Sep 22, 2026
Sep 9, 2026Seymour MelissaEVP, Global Qualitygift12$0.00—1,038Sep 11, 2026
Sep 2, 2026Hernandez EdgardoEVP & Pres., Mfg. Operationsgift13$0.00—46,083Sep 4, 2026
Sep 2, 2026Dozier EricEVP, Chief People Officergift216$0.00—14,239Sep 4, 2026
Aug 17, 2026Sulzberger GabrielleDirectoraward4$1183.16$5K3,004Aug 18, 2026
Aug 17, 2026Luciano Juan RDirectoraward13$1183.16$16K16,918Aug 18, 2026
Aug 17, 2026Fyrwald J ErikDirectoraward8$1183.16$10K75,418Aug 18, 2026
Aug 17, 2026Alvarez RalphDirectoraward10$1183.16$12K55,745Aug 18, 2026
Aug 17, 2026Jonsson PatrikEVP & President, LLY Int'lopen-market sale10b5-16,500$1175.10$8M54,147Aug 18, 2026
Aug 10, 2026Zakrowski Donald ASVP, Finance, & CAOopen-market sale10b5-12,000$1185.01$2M1,526Aug 11, 2026
Aug 7, 2026Hakim AnatEVP, GC & Secretaryopen-market sale10b5-1indirect5,000$1190.00$6M11,875Aug 10, 2026
Aug 1, 2026Seymour MelissaEVP, Global Qualityoption exercise981$0.00—1,506Aug 3, 2026
Aug 1, 2026Seymour MelissaEVP, Global Qualitytax withholding439$1148.84$504K1,067Aug 3, 2026
Jul 20, 2026Sulzberger GabrielleDirectoraward4$1146.90$5K3,000Jul 21, 2026
Jul 20, 2026Luciano Juan RDirectoraward14$1146.90$16K16,905Jul 21, 2026
Jul 20, 2026Fyrwald J ErikDirectoraward9$1146.90$10K75,410Jul 21, 2026
Jul 20, 2026Alvarez RalphDirectoraward11$1146.90$12K55,734Jul 21, 2026
Jun 15, 2026Sulzberger GabrielleDirectoraward4$1129.35$5K2,995Jun 16, 2026

Full insider history for Eli Lilly, or insider activity across all companies. A record of filings, not a recommendation.

Tracked funds holding it

2 of the tracked managers held LLY in their latest 13F filing, through August 14, 2026. Weight is the share of the fund’s reported portfolio. How the funds have traded LLY by quarter.

FundManagerQuarterValueSharesWeightMove
Duquesne Family OfficeStanley DruckenmillerQ2 2026$15M12,3800.28%new
Baron Capital GroupRon BaronQ2 2026$169M140,5400.25%added +65.2%

Sources

Fiscal year ends in month 12; periods are labeled with the issuer's own fiscal calendar. Values are as most recently filed (restatements apply; per-share values are on current split basis per the connector's split table, flagged in adjusted). Flow items flagged in `derived` were computed (Q4 = FY − nine months; quarterly cash flow differenced from year-to-date filings) rather than read from a filing. `reconciliation.repaired` lists periods where a full-year figure was filed in a quarter slot: that row was dropped and the quarter rebuilt from the annual figure. `reconciliation.quarantined` lists periods where four filed quarters do not sum to the filed year — those quarterly values are withheld, so a blank there is a withholding rather than an absence of reporting.

Filer
ELI LILLY AND COMPANY, CIK 59478 on EDGAR
Extract generated
October 30, 2026
Withheld
5 line-years whose four quarters do not sum to the filed year: buybacks FY2016, other income FY2016, cost of revenue FY2017, pretax income FY2017, revenue FY2017
Repaired
1 quarters where a full-year figure was filed in a quarter slot and the quarter was rebuilt: other income FY2022
XBRL concepts behind each line

Income statement

Revenue: Revenues
Cost of revenue: CostOfGoodsAndServicesSold
Gross profit: not filed
Research and development: ResearchAndDevelopmentExpense
Selling, general and administrative: SellingGeneralAndAdministrativeExpense
Operating income: not filed
Other income (expense): NonoperatingIncomeExpense, OtherNonoperatingIncomeExpense
Pretax income: IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest, IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments
Income tax: IncomeTaxExpenseBenefit
Net income: NetIncomeLoss
Diluted EPS ($): EarningsPerShareDiluted
Diluted shares (millions): WeightedAverageNumberOfDilutedSharesOutstanding

Balance sheet

Cash and equivalents: CashAndCashEquivalentsAtCarryingValue
Short-term investments: ShortTermInvestments
Total current assets: AssetsCurrent
Total assets: Assets
Total current liabilities: LiabilitiesCurrent
Long-term debt: LongTermDebtNoncurrent
Total liabilities: not filed
Stockholders’ equity: StockholdersEquity
Shares outstanding (millions): dei:EntityCommonStockSharesOutstanding

Cash flow statement

Operating cash flow: NetCashProvidedByUsedInOperatingActivities
Capital expenditures: PaymentsToAcquireProductiveAssets
Free cash flow (CFO − capex): not filed
Depreciation and amortization: DepreciationDepletionAndAmortization
Share repurchases: PaymentsForRepurchaseOfCommonStock
Dividends paid: PaymentsOfDividends

The data

The statements on this page as files, generated October 30, 2026.

JSON file
/data/financials/LLY.json